

List of Figures

Figure No.	Description	Page No.
5.1	Calibration curve of Genistein in methanol	49
5.2	Calibration curve of Paclitaxel in methanol	50
5.3	Calibration curve of Genistein in combination of Gen & PTX prepared in methanol	50
5.4	Calibration curve of Paclitaxel in combination of Gen & PTX prepared in methanol	51
5.5	Calibration curve of Genistein in plasma	51
5.6	Calibration curve of Paclitaxel in plasma	52
5.7	Calibration curve of Genistein in combination of Gen & PTX prepared in plasma	52
5.8	Calibration curve of Paclitaxel in combination of Gen & PTX prepared in plasma	53
5.9	CI and DRI plots for different F_a values	58
5.10	Pareto chart showing the influence of process variables on polydispersity index, particle size & entrapment efficiency	63
5.11	Graphical representation of effect of independent variables (lipid concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable (particles size (Y1)).	66
5.12	Graphical representation of effect of independent variables (lipid concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable (Entrapment Efficiency (Y2)).	69
5.13	Graphical representation of effect of independent variables (lipid concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable (Polydispersity Index (Y3)).	71
5.14	(A) Overlay FTIR spectra of Gen NLCs (A1), (B) Overlay FTIR spectra of PTXNLCs (A2), (C) Overlay FTIR spectra of combination NLCs (A3), Physical mixture (A1, A2 & A3 PM), Gen (D2),PTX (D3), Gen+ PTX (D2+D3) and all the excipients respectively.	74
5.15	DSC thermograms of (A) Genistein (D1) and Gen loaded NLCs	76

	(A1). (B) Paclitaxel (D3) and PTX loaded NLCs (A2), (C) combination of both drugs (D2+D3) and their NLCs (A3), physical mixture (A1, A2, A3 PM) and all excipients.	
5.16	P-XRD spectra of (A) Genistein (D2) and Gen loaded NLCs (A1). (B) Paclitaxel (D3) and PTX loaded NLCs (A2), (C) combination of both drugs (D2+D3) and their NLCs (A3) and all excipients.	77
5.17	Transmission electron microscopic images of optimized formulations (A- Gen NLCs, B- PTX NLCs & C- Gen+PTX NLCs).	79
5.18	Atomic force microscopic (AFM) images of optimized formulations (A- Gen NLCs, B- PTX NLCs & C- Gen+PTX NLCs)	79
5.19	In vitro drug release profile of A1, A2 & their pure drug suspensions in phosphate buffer saline pH 7.4. Vertical bars represent S.D, n=3.	81
5.20	In vitro drug release profile of A3 & its pure drug suspension in phosphate buffer saline pH 7.4. Vertical bars represent S.D, n=3.	81
5.21	Shelf life estimation of optimized batches of NLCs (A1, A2 & A3) at various conditions.	83
5.22	Heamolysis profiles of A1, A2 & A3 nanoparticles, placebo and pure drug suspensions at different concentrations.	85
5.23	No. of platelets after addition of (A) A1, Gen (B) A2, PTX (C) A3, Gen+PTX; PBS & Placebo at 10 & 100 µg/ml. Vertical bars represent S.D, n=3. *Data is non significantly different at p<0.05 from PBS (negative control).	87
5.24	Platelet aggregation optical microscopy images of Leishman's stained whole blood samples after treatment with PBS at 10 & 100 µg/ml, pure drug suspensions (PTX, Gen & PTX+Gen) at 10 & 100 µg/ml, Placebo formulation at 10 & 100 µg/ml & optimized formulations (A1, A2 & A3) at 10 & 100 µg/ml. Images were captured at magnification of 100x.	88
5.25	% cell viability of pure drug suspensions (PTX, Gen & PTX+Gen), optimized formulations (A1, A2 & A3) & placebo at different concentrations. Results were analyzed by two way ANOVA followed by bonferroni posthoc test; @: when compared with Gen at p< 0.05, !: when compared with PTX p< 0.001, #: when compared with Gen+PTX p< 0.0001; Values are expressed as mean± SD, n=3.	89
5.26	Scatter plot for the calculation of IC ₅₀ value.	90

5.27	Comparative plasma drug concentration vs. time profile of Gen, PTX, A1, & A2 after intravenous administration. Dose administered was 10 mg/kg. Each data point represents mean \pm SEM, at $p < 0.05$.	92
5.28	Comparative plasma drug concentration vs. time profile of Gen & PTX in pure drug combination, Gen & PTX in combination formulation after intravenous administration. Dose administered was 10 mg/kg. Each data point represents mean \pm SEM, at $p < 0.05$.	93
5.29	Blood serum levels of (A) Aspartate aminotransferase (AST or SGOT) (B) alkaline phosphatase (ALP), (C) alanine transaminase (ALT or SGPT) (D) Total bilirubin and (E) absolute neutrophil count (ANC) after the administration of A2 & A3 which were compared with their respective pure drug suspensions at a dose of 10mg/kg. 0.9% saline act as control. Each data point represents mean \pm SD, @ at $p < 0.0001$, # at $p < 0.001$, ! at $p < 0.05$ and * at $p < 0.0001$.	96
5.30	A) Graphical representation of % tumor growth vs. time (days) with treatments administered i.v. on the days mention on the graph. Error bars represent SEM, $n=3$, p value < 0.009 . (B) Representative image of tumor (c) Images of whole excised tumors for different test groups.	97
5.31	Tumor volume of combination formulation; A3 in comparison to its pure drug combination. Results were analyzed by two way ANOVA followed by bonferroni posthoc test ; (@ $p < 0.001$) & (# $p < 0.0001$).	98
5.32	Relative tumor growth rate of combination formulation; A3 in comparison to its pure drug combination. Results were analyzed by two way ANOVA followed by bonferroni posthoc test ; (@ $p < 0.001$) & (# $p < 0.0001$).	98
5.33	Graphical representation of effect of independent variables (Polymer concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable (particles size (Y1).	104
5.34	Graphical representation of effect of independent variables (Polymer concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable (polydispersity index (Y2)	106
5.35	Graphical representation of effect of independent variables (Polymer concentration (X1), amount of organic solvent (X2) & Surfactant concentration (X3)) on dependant variable entrapment	109

	efficiency (Y3).	
5.36	(A) Overlay FTIR spectra of Gen nanoparticles (B1), (B) Overlay FTIR spectra of PTX nanoparticles (B2), (C) Overlay FTIR spectra of combination nanoparticles (B3), Physical mixture (B1, B2 & B3 PM), Gen (D2),PTX (D3), Gen+ PTX (D2+D3) and all the excipients respectively.	112
5.37	DSC thermograms of (A) Genistein (D1) and Gen loaded nanoparticles (B1). (B) Paclitaxel (D3) and PTX loaded nanoparticles (B2), (C) combination of both drugs (D2+D3) and their nanoparticles (B3), physical mixture (B1, B2, B3 PM) and all excipients.	114
5.38	P-XRD spectra of (A) Genistein (D2) and Gen loaded nanoparticles (B1). (B) Paclitaxel (D3) and PTX loaded nanoparticles (B2), (C) combination of both drugs (D2+D3) and their nanoparticles (B3) and all excipients.	115
5.39	Transmission electron microscopic images of optimized formulations (A- Gen nanoparticles, B- PTX nanoparticles & C- Gen+PTX nanoparticles)	117
5.40	Atomic force microscopic (AFM) images of optimized formulations (A- Gen nanoparticles, B- PTX nanoparticles & C- Gen+PTX nanoparticles)	117
5.41	In vitro drug release profile of optimized formulations (B1& B2) and their pure drug solutions in phosphate buffer saline pH7.4. Vertical bars represent S.D, n=3.	119
5.42	In vitro drug release profile of optimized formulation (B3) and its pure drug suspension in phosphate buffer saline pH7.4. Vertical bars represent S.D, n=3.	119
5.43	Shelf life estimation of optimized batches of polymeric nanoparticles (B1, B2 & B3) at various conditions.	121
5.44	Heamolysis profiles of B1, B2 & B3 nanoparticles, placebo and pure drug suspensions at different concentrations.	123
5.45	No. of platelets after addition of (A) B1, Gen (B) B2, PTX (C) B3, Gen+PTX; PBS & Placebo at 10 & 100 µg/ml. Vertical bars represent S.D, n=3. *Data is non significantly different at p<0.05 from PBS (negative control).	124
5.46	Platelet aggregation optical microscopy images of Leishman's stained whole blood samples after treatment with PBS at 10 & 100 µg/ml, pure drug suspensions (PTX, Gen & PTX+Gen) at 10 & 100 µg/ml, Placebo formulation at 10 & 100 µg/ml & optimized formulations (B1, B2 & B3) at 10 & 100 µg/ml. Images were	125

	captured at magnification of 100x.	
5.47	% cell viability of pure drugs (PTX, Gen & PTX+Gen), optimized formulations (B1, B2 & B3) & placebo at different concentrations. Results were analyzed by two way ANOVA followed by Bonferroni posthoc test; *: when compared with pure Gen at $p < 0.05$, **: when compared with pure PTX $p < 0.001$, ***: when compared with pure drug combination of Gen+PTX $p < 0.0001$; Values are expressed as mean \pm SEM, $n=3$.	126
5.48	Scatter plot for the calculation of IC_{50} value.	127
5.49	Comparative plasma drug concentration vs. time profile of Gen, PTX, B1 and B2 after intravenous administration. Dose administered was 10 mg/kg. Each data point represents mean \pm SEM, at $p < 0.05$.	130
5.50	Comparative plasma drug concentration vs. time profile of Gen, PTX, in pure drug combination and in combination formulation B3 after intravenous administration. Dose administered was 10 mg/kg. Each data point represents mean \pm SEM, at $p < 0.05$.	130
5.51	Blood serum levels of (A) Aspartate aminotransferase (AST or SGOT) (B) alkaline phosphatase (ALP), (C) alanine transaminase (ALT or SGPT) (D) Total bilirubin and (E) absolute neutrophil count (ANC) after the administration of A2 & A3 which were compared with their respective pure drug suspensions at a dose of 10mg/kg. 0.9% saline act as control. Each data point represents mean \pm SD, @ at $p < 0.0001$, # at $p < 0.001$, ! at $p < 0.05$ and * at $p < 0.0001$.	133
5.52	(A) Graphical representation of % tumor growth vs. time (days) with treatments administered i.v. on the days mention on the graph. Error bars represent SEM, $n=3$, p value < 0.009 . (B) Representative image of tumor (c) Images of whole excised tumors for different test groups.	134
5.53	Tumor volume of combination formulation; B3 in comparison to its pure drug combination. Results were analyzed by two way ANOVA followed by Bonferroni posthoc test; (@ $p < 0.001$) & (# $p < 0.0001$).	135
5.54	Relative tumor growth rate of combination formulation; B3 in comparison to its pure drug combination. Results were analyzed by two way ANOVA followed by Bonferroni posthoc test ; (@ $p < 0.001$) & (# $p < 0.0001$).	135
